TransHeps AG

Safer drugs for patients via DILI causality assessments.

TransHeps develops MetaHeps®, a human PBMC-derived cell platform to assess drug-induced liver injury (DILI) in clinical development. Our assay focuses on immune-mediated DILI, one of the most unpredictable and costly causes of trial delays and drug withdrawals. We provide retrospective case assessment services and are developing a scalable DILI assessment kit for pharma and biotech sponsors. By generating patient-specific functional data, we support causality assessment, de-risk clinical programs, and aim to advance toward FDA qualification. The addressable market includes global drug developers facing high safety-related attrition and regulatory pressure.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

27.01.2026

FDA review status

25.02.2024

Successful FDA hearing

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (10'000) 2024

Website